Joint Symposium 2  
Oncology & Theranostics Committee / European Association of Urology (EAU)  
Sunday, October 16, 16:45-18:15

Session Title  
Prostate Cancer Radionuclide Therapy

Chairpersons  
Sarah Schwarzenböck (Rostock, Germany)  
Jochen Walz (Marseille, France / EAU)

Programme  
16:45 - 17:10  Jochen Walz (Marseille, France / EAU): Systemic Treatment Landscape of Prostate Cancer

17:10 - 17:30  Helle Zacho (Aalborg, Denmark): Response Assessment for Bone Disease in mCRPC by imaging - What Do We Need?

17:30 - 17:55  Sarah Schwarzenböck (Rostock, Germany): LuPSMA Radionuclide Therapy - Where Do We Stand and What’s Next?

17:55 - 18:15  James Nagarajah (Nijmegen, Netherlands): Alpha-Emitting PSMA-Radioligand Therapy - Ready for the Future?

Educational Objectives  
1. To learn the landscape and sequencing of mCRPC treatment in prostate cancer  
2. To summarize the current status and expected future developments of beta and alpha-emitting PSMA radioligand therapy  
3. To learn the challenges and options for assessing imaging response of bone metastases

Summary  
Treatment of metastatic castration resistant prostate cancer (mCRPC) is complex and multiple therapeutic agents are approved. With the advent of LuPSMA to be approved this treatment will be further integrated into nuclear medicine practice. The aim of the joint EAU/EANM session is to teach the audience the current therapeutic options for mCRPC, it’s sequencing and the clinical needs from a urologist’s point of view. The current experience, regulatory status of LuPSMA will be discussed and their potential futures development will be outlined. A special focus will be put on alpha-emitter treatment.

Key Words  
prostate cancer, radioligand therapy, Radium-223-dichlorid, alpha-emitter